Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HTR5A | P47898 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087803 | 0.87 | KDR (0.45) | EGFRPDGFRBABL1PRKCAKDR | |
| SCHEMBL4042509 | 0.86 | KDR (0.51) | EGFRPDGFRBABL1KDRHTR2B | |
| SCHEMBL4040017 | 0.86 | EGFR (0.51) | EGFRPDGFRBERBB2ABL1PRKCA | |
| SCHEMBL4043559 | 0.84 | PDGFRB (0.53) | EGFRPDGFRBKDR | |
| SCHEMBL4041898 | 0.84 | PDGFRB (0.53) | EGFRPDGFRBABL1PRKCAKDR | |
| SCHEMBL4043619 | 0.83 | PDGFRB (0.46) | EGFRPDGFRBERBB2ABL1PRKCA | |
| SCHEMBL4045623 | 0.82 | PDGFRB (0.42) | EGFRPDGFRBKDRAURKB | |
| SCHEMBL4041095 | 0.82 | PDGFRB (0.45) | EGFRPDGFRBABL1PRKCAKDR | |
| SCHEMBL4044946 | 0.80 | PDGFRB (0.55) | PDGFRB | |
| SCHEMBL4040264 | 0.80 | FLT3 (0.43) | EGFRPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | EGFR 26/4885PDGFRB 2/4885ERBB2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.